HomeStructural heart diseaseValvular Aortic valve

Valvular Aortic valve

View Category

Other

Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure...
solaci -
Learn More
Structural heart disease

TAVR in Low-Risk Patients: Though still Superior, with Diminished Advantage after 2 Years.

At two-year followup, primary end point continued to be significantly lower with Sapien 3 vs. conventional surgery,...
solaci -
Learn More
Antithrombotic Anticoagulants

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are...
solaci -
Learn More
Structural heart disease

Improvements in COAPT Trial for Functional Mitral Regurgitation

Patients with heart failure and moderate-to-severe secondary mitral regurgitation may benefit from transcatheter mitral valve repair. There...
solaci -
Learn More
Chronic Ischemic cardiopathy

Revascularization Is Needed Before TAVR

Disease prevalence in patients with severe aortic stenosis is highly variable: from 80% in inoperable patients to...
solaci -
Learn More
Structural heart disease

Data that Can Change TAVR and SAVR Strategy

In many relatively young patients with severe aortic stenosis, we rule out the idea of a mechanical...
solaci -
Learn More
Structural heart disease

Predilation in TAVR and Myocardial Injury

Performing balloon predilation or valvuloplasty before a transcatheter aortic valve replacement (TAVR) may increase the incidence and...
solaci -
Learn More
Structural heart disease

Coronary Access After TAVR: A Potential Problem Ahead

Coronary cannulation after transcatheter aortic valve replacement (TAVR) was unsuccessful in almost 10% of patients. This problem...
solaci -
Learn More